R&D Costs and Productivity in Biopharmaceuticals
This article characterizes the activities required to launch a new pharmaceutical molecule into the market, summarizes studies that have attempted to pinpoint the research and development costs incurred per approved new molecule, and analyzes the various critiques levied against published R&D cost estimates. It finds that by any reckoning, R&D costs per approved molecule have risen sharply over time, most likely at a rate of approximately 7 percent per year after stripping out the effects of general economic inflation.
Year of publication: |
2011-12
|
---|---|
Authors: | Scherer, F. M. |
Institutions: | Kennedy School of Government, Harvard University |
Saved in:
freely available
Saved in favorites
Similar items by person
-
Competition Policy and Intellectual Property: Insights from Developed Country Experience
Scherer, F. M., (2014)
-
Class Actions in the U.S. Experience: An Economist's Perception
Scherer, F. M., (2007)
-
How Conservative Economics Has Influenced Antitrust
Scherer, F. M., (2007)
- More ...